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Introduction
There is an unmet need for novel and effective treatments
for lymphoma, the fifth most common malignancy in the
US. In situ vaccination—an immunotherapeutic maneuver
involving local irradiation, intratumoral (i.t.) injections of
Flt3L and Toll-like receptor (TLR) agonist—has been
shown in recent clinical trials (NCT00185965,
NCT00880581, NCT00226993) to induce partial and com-
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plete remissions in patients with low-grade lymphoma[1].
The strength of anti-tumor response correlates with the
potency of immunogenic dendritic cells (DCs) to effi-
ciently uptake and present tumor antigens to T cells[2].
While the latest clinical trial NCT01976585 employs Poly-
ICLC—a synthetic TLR3 agonist—to activate DCs, we
hypothesize that “natural” TLR agonists (nTLRa) con-
tained within prophylactic vaccines could simultaneously
target multiple TLRs and be repurposed as clinical-grade
DC activators for the in situ vaccination maneuver[3].
Methods
Twenty-four prophylactic vaccines were screened for TLR
ligand activity using in vitro assays. DC subsets CD11c
+MHC-II+, CD11c+CD11b+, and CD11c+CD103+ were
gated for: (i.) activation markers (e.g. CD80, CD86, MHC
I, II), (ii.) ability to co-stimulate T cells in the context of
TCR activation, as assessed by T cell activation markers (e.
g. CD69, intracellular IFNg), and (iii.) ability of nTLRa-
activated DCs to induce T cell proliferation. TLR
knock-out cell lines were used for dissecting the mechan-
istically-distinct properties of each prophylactic vaccine.
Best single and combination nTLRa candidates were eval-
uated with the in situ vaccination maneuver in an in vivo
A20 murine lymphoma model.
Results
We identify a combination of vaccines Typhim, BCG-
TICE, and MMR that possess the ability to induce high
expression of costimulatory molecules on DCs in vitro
(Figure 1), as well as co-stimulating in vitro T cell activa-
tion and proliferation. DC costimulation of T cell activa-
tion and proliferation is highly dependent on the “live”
status of several vaccines, including BCG, MMR, Zostavax,
suggesting the involvement of other pattern-recognition
receptors in addition to TLRs. Cohorts of mice implanted
with A20 lymphoma tumors that received i.t. injections of
Typhim, BCG, MMR demonstrated slower tumor growth
status as compared to the control cohort receiving only
Flt3L and local irradiation (Figure 2).
Conclusions
Prophylactic vaccines contain natural ligands to TLRs and
are immediately translatable as sources of clinical-grade
stimulators of dendritic cells. Combinations of the best
nTLRa candidates display synergistic activation of DCs
and in vivo anti-A20 murine lymphoma immunity.
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